Connection
Scott Cramer to Enzyme Inhibitors
This is a "connection" page, showing publications Scott Cramer has written about Enzyme Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.404 |
|
|
|
-
Axanova LS, Chen YQ, McCoy T, Sui G, Cramer SD. 1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells. Prostate. 2010 Nov 01; 70(15):1658-71.
Score: 0.273
-
Schlaepfer IR, Rider L, Rodrigues LU, Gij?n MA, Pac CT, Romero L, Cimic A, Sirintrapun SJ, Glod? LM, Eckel RH, Cramer SD. Lipid catabolism via CPT1 as a therapeutic target for prostate cancer. Mol Cancer Ther. 2014 Oct; 13(10):2361-71.
Score: 0.089
-
Rao A, Coan A, Welsh JE, Barclay WW, Koumenis C, Cramer SD. Vitamin D receptor and p21/WAF1 are targets of genistein and 1,25-dihydroxyvitamin D3 in human prostate cancer cells. Cancer Res. 2004 Mar 15; 64(6):2143-7.
Score: 0.043